OPHD 001

Drug Profile

OPHD 001

Alternative Names: Clostridium difficile antibodies - Promega

Latest Information Update: 22 Nov 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Promega Corporation
  • Class Antibacterials; Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Clostridium infections

Most Recent Events

  • 08 Jun 2000 Ophidian has suspended research and product development operations
  • 08 Jun 2000 Suspended-I for Clostridium infections in USA (PO)
  • 11 Jun 1999 OPHD 001 has been named as Ophidian Pharmaceuticals' lead drug candidate for the treatment of Clostridium difficile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top